A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

• Status: NOT_YET_RECRUITING
• Trial end date: 2033-05-01

Summary

The purpose of the study is to assess the efficacy and safety of the addition of LY4064809 to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.

• Phase: PHASE3

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Pfizer
• Treatments: abemaciclib; Anastrozole; exemestane; Fulvestrant; Letrozole; palbociclib; ribociclib; STX-478